Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02365701 · ClinicalTrials.gov registry record · Phase 2

Study of Motilitone to Treat Functional Dyspepsia

A Phase 2 study of Dyspepsia, sponsored by Dong-A ST Co..

Completed
Registry status
Phase 2
Development phase
45
Enrollment target
1
Study location

NCT02365701 is a Phase 2 study of Dyspepsia that has completed, run by Dong-A ST Co.. The registered enrollment target is 45 participants, below the 73-participant average among 11 other Dyspepsia trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02365701, a Phase 2 study of Dyspepsia, has completed, sponsored by Dong-A ST Co..

COMPLETED
Registry status
Phase 2
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test.

Conditions Studied

Dyspepsia

Interventions

  • DRUG Placebo
  • DRUG Motilitone 30mg

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2015-06
Est. Completion 2018-02
Phase Phase 2

Sponsor

Dong-A ST Co.

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02365701

The ClinicalTrials.gov registry entry for NCT02365701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 73-participant average among 11 other Dyspepsia trials with a reported enrollment target (38% lower). The listed sponsor is Dong-A ST Co., which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dyspepsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02365701 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02365701 about?

NCT02365701 is a clinical study titled "Study of Motilitone to Treat Functional Dyspepsia". This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test.

What is the current status of trial NCT02365701?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-06. Estimated completion is 2018-02.

What conditions does trial NCT02365701 study?

This clinical trial studies the following conditions: Dyspepsia.

What interventions are being tested in trial NCT02365701?

The interventions under investigation include: Placebo (DRUG), Motilitone 30mg (DRUG).

Who is sponsoring clinical trial NCT02365701?

This trial is sponsored by Dong-A ST Co., which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02365701 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dyspepsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dyspepsia

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.